What is Rosidoc?
Rosidoc (Rosidoc) belongs to a a group of drugs called HMG CoA reductase inhibitors, or "statins." Rosidoc reduces levels of "bad" cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL).
Rosidoc is used in adults and children who are at least 8 years old to lower cholesterol and triglycerides (types of fat) in the blood and to slow the build-up of plaque (fatty deposits) in your blood vessels.
Rosidoc is also used to lower the risk of stroke, heart attack, and other heart complications in certain people with diabetes, coronary heart disease, or other risk factors.
Rosidoc is also used to treat hereditary forms of high cholesterol, including the heterozygous type (inherited from one parent) and the homozygous type (inherited from both parents). For the heterozygous type, Rosidoc can be used in children who are at least 8 years old. For the homozygous type, Rosidoc can be used in children as young as 7 years old.
Rosidoc indications
Rosidoc should be used as an adjunct to diet when the response to diet and exercise is inadequate.
Prevention of Cardiovascular Events: In adult patients with an increased risk of atherosclerotic cardiovascular disease based on the presence of cardiovascular disease risk markers such as an elevated hsCRP level, age, hypertension, low HDL-C, smoking or a family history of premature coronary heart disease, Rosidoc is indicated to reduce total mortality and the risk of major cardiovascular events (cardiovascular death, stroke, MI, unstable angina, or arterial revascularization).
In Adult Patients with Hypercholesterolaemia: Rosidoc is indicated to: Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDL-cholesterol in patients with primary hypercholesterolaemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). Rosidoc also lowers ApoB, nonHDL-C, VLDL-C, VLDL-TG, the LDL-C/HDL-C, total C/HDL-C, nonHDL-C/HDL-C, ApoB/ApoA-I ratios and increases ApoA-I in these populations.
Treat patients with primary dysbetalipoproteinaemia (Fredrickson Type III hyper lipoproteinaemia).
Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia).
Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolaemia, as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or alone if such treatments are unavailable.
Slow or delay the progression of atherosclerosis.
Children and Adolescents 6 to 17 Years of Age: Rosidoc is indicated to reduce the Total Cholesterol, LDL-C and Apo B in patients with heterozygous familial hypercholesterolaemia (HeFH).
How should I use Rosidoc?
Use Rosidoc as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Rosidoc. Talk to your pharmacist if you have questions about this information.
- Take Rosidoc by mouth with or without food.
- Swallow the tablets whole.
- If you also take an antacid that has aluminum or magnesium in it, take it at least 2 hours after taking Rosidoc. Check with your doctor if you have any questions.
- Taking Rosidoc at the same time each day will help you remember to take it.
- Continue to take Rosidoc even if you feel well. Do not miss any doses.
- If you miss a dose of Rosidoc, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once or within 12 hours of each other.
Ask your health care provider any questions you may have about how to use Rosidoc.
Uses of Rosidoc in details
- Rosidoc is used for the treatment of high cholesterol, high LDL, high triglycerides and low HDL in addition to diet, when response to non-medicine options (diet, exercise and weight loss) is not adequate.
- It is also used to lower the risk of stroke, heart attack, or other heart complications in people who are at high risk of heart diseases, as an adjuvant to correction of the risk factors.
Rosidoc description
Rosidoc also contains the following inactive ingredients: Tribasic calcium phosphate, microcrystalline cellulose (PH 102), butylated hydroxy toluene, povidone K-30, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, Instacoat universal white IH, purified water; color: Titanium dioxide.
Rosidoc is a synthetic lipid-lowering agent for oral administration. The chemical name for Rosidoc calcium is bis[(E)-7-[4(4-fluorophenyl)-6-isopropyl 2[methyl (methylsulfonyl) amino] pyrimidin-5-yl](3R,5S)3,5-dihydroxyhept-6-enoic acid] calcium salt. The empirical formula is (C22H27FN3O6S)2Ca and the molecular weight is 1001.14.
Rosidoc dosage
General Dosing Information: The dose range for Rosidoc is 5-40 mg orally once daily.
Rosidoc can be administered as a single dose at any time of the day, with or without food. When initiating Rosidoc therapy or switching from another HMG-CoA reductase inhibitor therapy, the appropriate Rosidoc starting dose should first be utilized, and only then titrated according to the patient's response and individualized goal of therapy.
The 40 mg dose of Rosidoc should be used only for those patients who have not achieved their LDL-C goal utilizing the 20 mg dose.
Hyperlipidemia, Mixed Dyslipidemia, Hypertriglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) and Slowing of the Progression of Atherosclerosis: The recommended starting dose of Rosidoc is 10 mg dose once daily. For patients with marked hyperlipidemia (LDL-C >190 mg/dL) and aggressive lipid targets, a 20 mg starting dose may be considered.
After initiation or upon titration of Rosidoc, lipid levels should be analyzed within 2-4 weeks and the dosage adjusted accordingly.
Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years): The usual dose range of Rosidoc is 5-20 mg/day; the maximum recommended dose is 20 mg/day (doses >20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy. Adjustments should be made at intervals of ≥4 weeks.
Homozygous Familial Hypercholesterolemia: The recommended starting dose of Rosidoc is 20 mg once daily. Response to therapy should be estimated from pre-aphereses LDL-C levels.
Dosage in Asian Patients: Initiation of Rosidoc therapy with 5 mg once daily should be considered for Asian patients.
Use with Cyclosporine or Lopinavir/Ritonavir: In patients taking cyclosporine, the dose of Rosidoc should be limited to 5 mg once daily. In patients taking a combination of lopinavir and ritonavir, the dose of Rosidoc should be limited to 10 mg once daily.
Concomitant Lipid-Lowering Therapy: The risk of skeletal muscle effects may be enhanced when Rosidoc is used in combination with niacin or fenofibrate; a reduction in Rosidoc is used in combination with gemfibrozil, the dose of Rosidoc should be limited to 10 mg daily.
Dosage in Patients with Severe Renal Impairment: For patients with severe renal impairment (CrCl <30 mL/min/1.73 m2) not on hemodialysis, dosing of Rosidoc should be started at 5 mg once daily and should not exceed 10 mg once daily.
Rosidoc interactions
See also:
What other drugs will affect Rosidoc?
Effect of Co-Administered Medicinal Products on Rosidoc: In vitro and in vivo data indicate that Rosidoc has no clinically significant cytochrome P450 interactions (as a substrate, inhibitor or inducer). Rosidoc is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of Rosidoc with medicinal products that are inhibitors of these transporter proteins may result in increased Rosidoc plasma concentrations and an increased risk of myopathy.
Interactions Requiring Rosidoc Dose Adjustments : When it is necessary to co-administer Rosidoc with other medicinal products known to increase exposure to Rosidoc, doses of Rosidoc should be adjusted. It is recommended that prescribers consult the relevant product information when considering administration of such products together with Rosidoc. Start with a 5 mg once daily dose of Rosidoc if the expected increase in exposure (AUC) is approximately 2-fold or higher. The maximum daily dose of Rosidoc should be adjusted so that the expected Rosidoc exposure would not likely exceed that of a 40 mg daily dose of Rosidoc taken without interacting medicinal products, for example a 5 mg dose of Rosidoc with ciclosporin (7.1-fold increase in exposure), a 10 mg dose of Rosidoc with ritonavir/atazanavir combination (3.1-fold increase) and a 20 mg dose of Rosidoc with gemfibrozil (1.9-fold increase).
Other Interacting Medicinal Products: Antacid: The simultaneous dosing of Rosidoc with an antacid suspension containing aluminum and magnesium hydroxide resulted in a decrease in Rosidoc plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after Rosidoc. The clinical relevance of this interaction has not been studied.
Fusidic Acid: Interaction studies with Rosidoc and fusidic acid have not been conducted. As with other statins, muscle related events, including rhabdomyolysis, have been reported in post-marketing experience with Rosidoc and fusidic acid given concurrently. Patients should be closely monitored and temporary suspension of Rosidoc treatment may be appropriate.
Effect of Rosidoc on Co-Administered Medicinal Products: Warfarin: The pharmacokinetics of warfarin are not significantly affected following co-administration with Rosidoc. However, as with other HMG-CoA reductase inhibitors, co-administration of Rosidoc and warfarin may result in a rise in INR compared to warfarin alone. In patients taking vitamin K antagonists monitoring of INR is recommended both at initiation or cessation of therapy with Rosidoc or following dose adjustment.
Fenofibrates/Fibric Acid Derivatives: Although no pharmacokinetic interaction between Rosidoc and fenofibrate was observed; a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate and other fibric acids, including nicotinic acid, may increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors.
Cyclosporin: Co-administration of Rosidoc with cyclosporin resulted in no significant changes in cyclosporin plasma concentration.
Other Medications: There were no clinically significant interactions with an oral contraceptive, digoxin, ezetimibe, or fenofibrate.
In clinical studies Rosidoc was co-administered with antihypertensive agents, antidiabetic agents and hormone replacement therapy. These studies did not produce any evidence of clinically significant adverse interactions.
Rosidoc side effects
See also:
What are the possible side effects of Rosidoc?
Rosidoc is generally well tolerated. The adverse events seen with Rosidoc are generally mild and transient. In controlled clinical trials less than 4% of Rosidoc treated patients were withdrawn due to adverse events. This withdrawal rate was comparable to that reported in patients receiving placebo.
Common (≥1/100, <1/10): Headache, myalgia, asthenia, constipation, dizziness, nausea, abdominal pain, diabetes mellitus*.
Uncommon (≥1/1000, <1/100): Pruritus, rash and urticaria.
Rare (≥1/10,000, <1/1000): Myopathy (including myositis), hypersensitivity reactions (including angioedema), rhabdomyolysis, pancreatitis.
*Observed in the JUPITER study (reported overall frequency 2.8% in Rosidoc and 2.3% in placebo) primarily in patients already at high risk for developing diabetes.
As with other HMG CoA reductase inhibitors, the incidence of adverse drug reactions tends to increase with increasing dose.
Skeletal Muscle Effects: Rare cases of rhabdomyolysis, which were occasionally associated with impairment of renal function, have been reported with Rosidoc and with other marketed statins.
Laboratory Effects: As with other HMG-CoA reductase inhibitors, a dose-related increase in liver transaminases and CK has been observed in a small number of patients taking Rosidoc. Increases in HbA1c have also been observed in patients treated with Rosidoc. Abnormal urinalysis testing (dipstick-positive proteinuria) has been seen in a small number of patients taking Rosidoc and other HMG-CoA reductase inhibitors. The protein detected was mostly tubular in origin. In most cases, proteinuria decreases or disappears spontaneously on continued therapy, and is not predictive of acute or progressive renal disease.
Other Effects: In a long-term controlled clinical trial Rosidoc was shown to have no harmful effects on the ocular lens.
In Rosidoc treated patients, there was no impairment of adrenocortical function.
Post Marketing Experience: In addition to the previously mentioned effects, the following adverse events have been reported during post marketing experience of Rosidoc: Haematological Disorders: Frequency Unknown: Thrombocytopenia.
Hepatobiliary Disorders: Very Rare: Jaundice, hepatitis. Rare: Increased hepatic transaminases.
Musculoskeletal Disorder: Frequency Unknown: Immune-mediated necrotising myopathy. Very Rare: Arthralgia.
As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis in post-marketing use is higher at the highest marketed dose.
Nervous System Disorder: Very Rare: Memory loss. Frequency Unknown: Peripheral neuropathy.
Psychiatric Disorders: Frequency Unknown: Depression, sleep disorders (including insomnia and nightmares).
Reproductive System and Breast Disorders: Frequency Unknown: Gynaecomastia.
Children and Adolescents 6 to 17 Years of Age: The safety profile of Rosidoc is similar in children or adolescent patients and adults although CK elevations >10 x ULN and muscle symptoms following exercise or increased physical activity, which resolved with continued treatment, were observed more frequently in clinical trial of children and adolescents. However, the same special warnings and special precautions for use in adults also apply to children and adolescents.
Rosidoc contraindications
See also:
What is the most important information I should know about Rosidoc?
Hypersensitivity to Rosidoc or to any of the excipients of Rosidoc Sandoz.
Hepatic impairment; severe renal impairment; repeated or unexplained muscle aches or pain (myopathy); ciclosporin (eg, used after organ transplants).
In addition, the 40 mg dose of Rosidoc Sandoz is contraindicated in: Repeated or unexplained muscle aches or pains (myopathy), a personal or family history of muscle problems or a previous history of muscle problems when taking other cholesterol-lowering drugs; moderate renal impairment; thyroid gland disorders; regular consumption of large amounts of alcohol; if taking fibrates to lower cholesterol; Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).
Use in pregnancy & lactation: Rosidoc Sandoz should not be taken by pregnant and breastfeeding women. If the patient become pregnant while taking Rosidoc Sandoz, stop taking it immediately and inform the physician. Women should avoid becoming pregnant while taking Rosidoc Sandoz by using suitable contraception.
Active ingredient matches for Rosidoc:
Rosuvastatin in India.
| Unit description / dosage (Manufacturer) | Price, USD |
| Rosidoc 10mg TAB / 10 | $ 0.84 |
| ROSIDOC tab 10 mg x 10's (Docventures) | $ 0.84 |
List of Rosidoc substitutes (brand and generic names): | |
| Rosevast (India) | |
| Rosevast 10mg Tablet (Neocardiabcare) | $ 0.08 |
| Rosimit | |
| Rosimit 5mg Tablet (Mitoch Pharma Pvt Ltd) | $ 0.06 |
| Rosimol (Chile) | |
| Rosistat (Bulgaria) | |
| Roslen | |
| Roslen 10mg Tablet (Aylen Pharmaceutical Pvt. Ltd.) | $ 0.13 |
| Roslen 20mg Tablet (Aylen Pharmaceutical Pvt. Ltd.) | $ 0.22 |
| Roslen 5mg Tablet (Aylen Pharmaceutical Pvt. Ltd.) | $ 0.08 |
| ROSLOY | |
| ROSLOY 20MG TABLET 1 strip / 10 tablets each (Lloyd) | $ 2.29 |
| ROSLOY tab 10 mg x 10's (Lloyd) | $ 1.18 |
| ROSLOY tab 20 mg x 10's (Lloyd) | $ 2.29 |
| Rosloy 10mg Tablet (Lloyd) | $ 0.12 |
| Rosloy 5mg Tablet (Lloyd) | $ 0.06 |
| Rosloy CV 5mg/75mg Tablet (Lloyd) | $ 0.14 |
| Rosloy CV Capsule (Lloyd) | $ 0.17 |
| Rosloy D 10mg/1000IU Tablet (Lloyd) | $ 0.13 |
| Rosloy D 5mg/1000IU Tablet (Lloyd) | $ 0.10 |
| Rosloy F 160mg/10mg Tablet (Lloyd) | $ 0.16 |
| Rosloy F 160mg/5mg Tablet (Lloyd) | $ 0.13 |
| Rosloy Gold 75mg/20mg/75mg Capsule (Lloyd) | $ 0.24 |
| Rosloy Gold Capsule (Lloyd) | $ 0.14 |
| Rosmi (India) | |
| Rosmi 10mg FC-TAB / 10 (Cadila) | $ 1.55 |
| ROSMI 10 MG TABLET 1 strip / 10 tablets each (Cadila) | $ 1.71 |
| ROSMI 20 MG TABLET 1 strip / 10 tablets each (Cadila) | $ 3.53 |
| ROSMI 40 MG TABLET 1 strip / 10 tablets each (Cadila) | $ 3.86 |
| ROSMI film-coated tab 10 mg x 10's (Cadila) | $ 1.55 |
| Rosmi 10mg Tablet (Cadila) | $ 0.17 |
| Rosmi 20mg Tablet (Cadila) | $ 0.35 |
| Rosmi 40mg Tablet (Cadila) | $ 0.39 |
| ROSORIS (India) | |
| ROSORIS tab 10 mg x 10's (Curis) | |
| Rossta (Poland) | |
| Rosstat (Bosnia & Herzegowina) | |
| Rost | |
| Rost 10mg Tablet (Hetero Drugs Ltd) | $ 0.08 |
| Rost 20mg Tablet (Hetero Drugs Ltd) | $ 0.13 |
| Rost 5mg Tablet (Hetero Drugs Ltd) | $ 0.04 |
| Rost F 160mg/10mg Tablet (Hetero Drugs Ltd) | $ 0.12 |
| Rost 10 (Vietnam) | |
| Rost 10 10 mg x 3 Blister x 10 Tablet | |
| ROSTA (India) | |
| 5 mg x 10's (Shrrishti HC) | |
| 10 mg x 10's (Shrrishti HC) | |
| 20 mg x 10's (Shrrishti HC) | |
| Rosta 5mg TAB / 10 (Shrrishti HC) | |
| Rosta 10mg TAB / 10 (Shrrishti HC) | |
| Rosta 20mg TAB / 10 (Shrrishti HC) | |
See 1846 substitutes for Rosidoc | |
References
- DailyMed. "ROSUVASTATIN CALCIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "Rosuvastatin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Rosuvastatin". http://www.drugbank.ca/drugs/DB01098 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Rosidoc are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Rosidoc. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
